Literature DB >> 33676569

Association of expression of epigenetic molecular factors with DNA methylation and sensitivity to chemotherapeutic agents in cancer cell lines.

Suleyman Vural1, Alida Palmisano1,2, William C Reinhold3, Yves Pommier3, Beverly A Teicher4, Julia Krushkal5.   

Abstract

BACKGROUND: Altered DNA methylation patterns play important roles in cancer development and progression. We examined whether expression levels of genes directly or indirectly involved in DNA methylation and demethylation may be associated with response of cancer cell lines to chemotherapy treatment with a variety of antitumor agents.
RESULTS: We analyzed 72 genes encoding epigenetic factors directly or indirectly involved in DNA methylation and demethylation processes. We examined association of their pretreatment expression levels with methylation beta-values of individual DNA methylation probes, DNA methylation averaged within gene regions, and average epigenome-wide methylation levels. We analyzed data from 645 cancer cell lines and 23 cancer types from the Cancer Cell Line Encyclopedia and Genomics of Drug Sensitivity in Cancer datasets. We observed numerous correlations between expression of genes encoding epigenetic factors and response to chemotherapeutic agents. Expression of genes encoding a variety of epigenetic factors, including KDM2B, DNMT1, EHMT2, SETDB1, EZH2, APOBEC3G, and other genes, was correlated with response to multiple agents. DNA methylation of numerous target probes and gene regions was associated with expression of multiple genes encoding epigenetic factors, underscoring complex regulation of epigenome methylation by multiple intersecting molecular pathways. The genes whose expression was associated with methylation of multiple epigenome targets encode DNA methyltransferases, TET DNA methylcytosine dioxygenases, the methylated DNA-binding protein ZBTB38, KDM2B, SETDB1, and other molecular factors which are involved in diverse epigenetic processes affecting DNA methylation. While baseline DNA methylation of numerous epigenome targets was correlated with cell line response to antitumor agents, the complex relationships between the overlapping effects of each epigenetic factor on methylation of specific targets and the importance of such influences in tumor response to individual agents require further investigation.
CONCLUSIONS: Expression of multiple genes encoding epigenetic factors is associated with drug response and with DNA methylation of numerous epigenome targets that may affect response to therapeutic agents. Our findings suggest complex and interconnected pathways regulating DNA methylation in the epigenome, which may both directly and indirectly affect response to chemotherapy.

Entities:  

Keywords:  Cancer drug treatment; DNA methylation; Epigenetic analysis; Gene expression

Mesh:

Substances:

Year:  2021        PMID: 33676569      PMCID: PMC7936435          DOI: 10.1186/s13148-021-01026-4

Source DB:  PubMed          Journal:  Clin Epigenetics        ISSN: 1868-7075            Impact factor:   6.551


  143 in total

Review 1.  Rad9, an evolutionarily conserved gene with multiple functions for preserving genomic integrity.

Authors:  Howard B Lieberman
Journal:  J Cell Biochem       Date:  2006-03-01       Impact factor: 4.429

2.  Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling.

Authors:  C Zeller; W Dai; N L Steele; A Siddiq; A J Walley; C S M Wilhelm-Benartzi; S Rizzo; A van der Zee; J A Plumb; R Brown
Journal:  Oncogene       Date:  2012-01-16       Impact factor: 9.867

3.  Silencing of ROR1 and FMOD with siRNA results in apoptosis of CLL cells.

Authors:  Aniruddha Choudhury; Katja Derkow; Amir Hossein Daneshmanesh; Eva Mikaelsson; Shahryar Kiaii; Parviz Kokhaei; Anders Osterborg; Håkan Mellstedt
Journal:  Br J Haematol       Date:  2010-08-31       Impact factor: 6.998

4.  Next-generation characterization of the Cancer Cell Line Encyclopedia.

Authors:  Mahmoud Ghandi; Franklin W Huang; Judit Jané-Valbuena; Gregory V Kryukov; Christopher C Lo; E Robert McDonald; Jordi Barretina; Ellen T Gelfand; Craig M Bielski; Haoxin Li; Kevin Hu; Alexander Y Andreev-Drakhlin; Jaegil Kim; Julian M Hess; Brian J Haas; François Aguet; Barbara A Weir; Michael V Rothberg; Brenton R Paolella; Michael S Lawrence; Rehan Akbani; Yiling Lu; Hong L Tiv; Prafulla C Gokhale; Antoine de Weck; Ali Amin Mansour; Coyin Oh; Juliann Shih; Kevin Hadi; Yanay Rosen; Jonathan Bistline; Kavitha Venkatesan; Anupama Reddy; Dmitriy Sonkin; Manway Liu; Joseph Lehar; Joshua M Korn; Dale A Porter; Michael D Jones; Javad Golji; Giordano Caponigro; Jordan E Taylor; Caitlin M Dunning; Amanda L Creech; Allison C Warren; James M McFarland; Mahdi Zamanighomi; Audrey Kauffmann; Nicolas Stransky; Marcin Imielinski; Yosef E Maruvka; Andrew D Cherniack; Aviad Tsherniak; Francisca Vazquez; Jacob D Jaffe; Andrew A Lane; David M Weinstock; Cory M Johannessen; Michael P Morrissey; Frank Stegmeier; Robert Schlegel; William C Hahn; Gad Getz; Gordon B Mills; Jesse S Boehm; Todd R Golub; Levi A Garraway; William R Sellers
Journal:  Nature       Date:  2019-05-08       Impact factor: 49.962

Review 5.  Cisplatin: mode of cytotoxic action and molecular basis of resistance.

Authors:  Zahid H Siddik
Journal:  Oncogene       Date:  2003-10-20       Impact factor: 9.867

6.  Aurora A Kinase Inhibition Is Synthetic Lethal with Loss of the RB1 Tumor Suppressor Gene.

Authors:  Xueqian Gong; Jian Du; Stephen H Parsons; Farhana F Merzoug; Yue Webster; Philip W Iversen; Li-Chun Chio; Robert D Van Horn; Xi Lin; Wayne Blosser; Bomie Han; Shaoling Jin; Sufang Yao; Huimin Bian; Chris Ficklin; Li Fan; Avnish Kapoor; Stephen Antonysamy; Ann M Mc Nulty; Karen Froning; Danalyn Manglicmot; Anna Pustilnik; Kenneth Weichert; Stephen R Wasserman; Michele Dowless; Carlos Marugán; Carmen Baquero; María José Lallena; Scott W Eastman; Yu-Hua Hui; Matthew Z Dieter; Thompson Doman; Shaoyou Chu; Hui-Rong Qian; Xiang S Ye; David A Barda; Gregory D Plowman; Christoph Reinhard; Robert M Campbell; James R Henry; Sean G Buchanan
Journal:  Cancer Discov       Date:  2018-10-29       Impact factor: 39.397

7.  Targeting NAD+ Biosynthesis Overcomes Panobinostat and Bortezomib-Induced Malignant Glioma Resistance.

Authors:  Esther P Jane; Daniel R Premkumar; Swetha Thambireddy; Brian Golbourn; Sameer Agnihotri; Kelsey C Bertrand; Stephen C Mack; Max I Myers; Ansuman Chattopadhyay; D Lansing Taylor; Mark E Schurdak; Andrew M Stern; Ian F Pollack
Journal:  Mol Cancer Res       Date:  2020-04-01       Impact factor: 5.852

Review 8.  Targeting the epigenome in lung cancer: expanding approaches to epigenetic therapy.

Authors:  Marko Jakopovic; Anish Thomas; Sanjeeve Balasubramaniam; David Schrump; Giuseppe Giaccone; Susan E Bates
Journal:  Front Oncol       Date:  2013-10-09       Impact factor: 6.244

9.  YAP and TAZ modulate cell phenotype in a subset of small cell lung cancer.

Authors:  Masafumi Horie; Akira Saito; Mitsuhiro Ohshima; Hiroshi I Suzuki; Takahide Nagase
Journal:  Cancer Sci       Date:  2016-11-25       Impact factor: 6.716

10.  SCLC-CellMiner: A Resource for Small Cell Lung Cancer Cell Line Genomics and Pharmacology Based on Genomic Signatures.

Authors:  Camille Tlemsani; Lorinc Pongor; Fathi Elloumi; Luc Girard; Kenneth E Huffman; Nitin Roper; Sudhir Varma; Augustin Luna; Vinodh N Rajapakse; Robin Sebastian; Kurt W Kohn; Julia Krushkal; Mirit I Aladjem; Beverly A Teicher; Paul S Meltzer; William C Reinhold; John D Minna; Anish Thomas; Yves Pommier
Journal:  Cell Rep       Date:  2020-10-20       Impact factor: 9.423

View more
  4 in total

1.  Cross talk between acetylation and methylation regulators reveals histone modifier expression patterns posing prognostic and therapeutic implications on patients with colon cancer.

Authors:  Rui Zhou; Fuli Xie; Kuncai Liu; Xuee Zhou; Xuemei Chen; Jinzhang Chen; Shaoyan Xi; Zhenhua Huang; Xiaoxiang Rong
Journal:  Clin Epigenetics       Date:  2022-05-23       Impact factor: 7.259

2.  miR-497-5p/SALL4 axis promotes stemness phenotype of choriocarcinoma and forms a feedback loop with DNMT-mediated epigenetic regulation.

Authors:  Zheng Peng; Yi Zhang; Dazun Shi; Yanyan Jia; Huirong Shi; Huining Liu
Journal:  Cell Death Dis       Date:  2021-11-03       Impact factor: 8.469

3.  An integrated analysis of DNA promoter methylation, microRNA regulation, and gene expression in gastric adenocarcinoma.

Authors:  Hongyun Huang; Lang Xie; Xiaoxuan Feng; Zheng Zheng; Juntao Ouyang; Yan Li; Jinlong Yu
Journal:  Ann Transl Med       Date:  2021-09

4.  Cisplatin resistance-related multi-omics differences and the establishment of machine learning models.

Authors:  Qihai Sui; Zhencong Chen; Zhengyang Hu; Yiwei Huang; Jiaqi Liang; Guoshu Bi; Yunyi Bian; Mengnan Zhao; Cheng Zhan; Zongwu Lin; Qun Wang; Lijie Tan
Journal:  J Transl Med       Date:  2022-04-11       Impact factor: 5.531

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.